HTRF Human Granzyme B Detection Kit is designed for the rapid detection of human Granzyme B in cell supernatant and whole cells.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Granzyme B (also called Cathepsin G-like 1, Cytotoxic T-lymphocyte proteinase 2, Fragmentin-2, Granzyme-2, or Human lymphocyte protein) is found in cytotoxic lymphocytes, NK (natural killer) cells, and cytotoxic T cells. Secreted with Perforin, which creates a pore in the cell membrane, it enters the target cell's cytoplasm and triggers apoptosis through caspase activation.
This kit is designed for the rapid detection of human Granzyme B in cell supernatant and whole cells. The assay enables high throughput without any washing steps, thereby saving time compared to ELISA.
Assay Points |
500
|
---|---|
Assay Technology |
HTRF
|
Brand |
HTRF
|
Product Group |
Kit
|
Quantity |
1
|
Shipping Conditions |
Shipped in Dry Ice
|
Therapeutic Area |
Oncology & Inflammation
|
Unit Size |
500 Tests
|
Human Granzyme B is a sandwich immunoassay involving two specific anti-human Granzyme B antibodies, respectively labelled with Europium Cryptate (donor) and d2 (acceptor). The intensity of the signal is proportional to the concentration of Granzyme B present in the sample.
The assay protocol, using a 384-well small volume white plate or a Revvity low volume 96-well plate (20 µL final), is described on the right. 16 µL of cell supernatant, sample, or standard are dispensed directly into the plate for detection by HTRF reagents. The antibodies labelled with HTRF donor and acceptor can be pre-mixed and added in a single dispensing step to further streamline the assay procedure. The assay can be run in 96- to 384-well plates by simply resizing each addition volume proportionally.
Sample size | 16 µL |
---|---|
Final assay volume | 20 µL |
Kit components | lyophilized standard, frozen detection antibodies, buffers & protocol |
LOD & LOQ (in diluent) | 1.8 ng/mL & 3.7 ng/mL |
Range | 3.7 – 1,500 ng/mL |
Time to result | ON at RT |
Recombinant Granzyme B provided in the kit (standard) was serially diluted in diluent #5, following the procedure given in the kit’s package insert. The HTRF signal, expressed as a delta ratio, was plotted as a function of the Granzyme B concentrations.
intra assay (n=24)
Sample | Mean [GranzymeB] (pg/mL) | CV |
---|---|---|
1 | 644 | 14% |
2 | 438 | 14% |
3 | 23 | 18% |
Mean CV | 15% |
Each of the 3 samples was measured 24 times, and % CV was calculated for each sample.
Inter assay (n=4)
Sample | [GranzymeB] (pg/mL) |
Mean (deltaRatio) |
CV |
---|---|---|---|
1 | 10 | 576 | 9% |
2 | 54 | 2759 | 6% |
3 | 652 | 18940 | 6% |
Mean CV | 7% |
Each of the samples was measured in 4 different experiments, and % CV was calculated for each sample.
Different cell densities (4K and 2K) of TALL-104 cells (Effector cells) were co-cultured with or without K-562 cells (Target cells) in suspension under 16µL in 384-well sv microplates. The cells were incubated for 16 hours at 37°C - 5% CO2. After co-culture, 4 µL of the HTRF Granzyme B detection reagents were added. The HTRF signal was recorded after an overnight incubation at RT.
Different cell densities (50K and 25K) of TALL-104 cells (Effector cells) were plated in suspension under 50µL in 96-well plates. TALL-104 cells were co-cultured with or without K-562 cells (Target cells) for 16 hours at 37°C - 5% CO2. After co-culture, 16µL of cell supernatants were transferred into a 384-well sv white microplate and 4 µL of the HTRF Granzyme B detection reagents were added. The HTRF signal was recorded after an overnight incubation at RT.
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
Advance your autoimmune disease research and benefit from Revvity broad offering of reagent technologies
Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.